Table 1.
Characteristics of Patients, IFIs, and Isavuconazole Therapy Courses
| No (%) or Median (Range) | |
|---|---|
| Patients | 113 |
| Age, y | 58 (16–83) |
| Sex | |
| Female | 42 (37) |
| Male | 71 (63) |
| Underlying conditions | |
| Allogeneic HSCT | 59 (52) |
| Hematologic cancer, non-HSCT | 22 (19) |
| Solid organ transplantation | 12 (11) |
| Autoimmune disease | 3 (3) |
| Influenza or COVID-19 | 2 (2) |
| No host criteria | 15 (13) |
| IFIsa | 114a |
| IFI classificationb | |
| Proven | 39 (34) |
| Probable | 23 (20) |
| Possible | 37 (32) |
| No IFIc | 15 (13) |
| Documentation of IFI | 62 |
| Invasive aspergillosisd | 40 (65) |
| Invasive mucormycosise | 12 (19) |
| Mixed aspergillosis/mucormycosis | 2 (3) |
| Other IFIf | 8 (13) |
| Localization of IFI | |
| Pulmonary only | 81 (71) |
| Extrapulmonary (single site) | 10 (9) |
| Multiple sites | 16 (14) |
| No clinical site | 7 (6) |
| Isavuconazole courses | 116g |
| Type of treatment | |
| First-line therapy | 45 (39) |
| Subsequent line of therapy | 66 (57) |
| Prophylaxish | 5 (4) |
| Isavuconazole monotherapy | 100 (86) |
| Other concomitant antifungal drugi | 16 (14) |
Abbreviations: EORTC-MSGERC, European Organization for Research and Treatment of Cancer–Mycoses Study Group Education and Research Consortium; HSCT, hematopoietic stem cell transplantation; IFI, invasive fungal infection; PCR, polymerase chain reaction.
aOne patient developed 2 IFIs at 202 days apart.
bAccording to definitions of the EORTC-MSGERC [11].
cIncludes chronic pulmonary aspergillosis (n = 5), antifungal prophylaxis (n = 5), and suspected IFI not meeting EORTC-MSGERC criteria (n = 5).
dDocumentation of Aspergillus spp (culture or PCR) or positive galactomannan (serum or bronchoalveolar lavage fluid).
eDocumentation of Mucorales by PCR or culture or presence of broad septate hyphae at histopathology.
fFungal pathogens (n = 1 each): Scedosporium apiospermum, Phaeoacremonium spp, Blastoschizomyces capitatus, Fusarium spp, Conidiobolus spp, Trichosporon asahii and Kodamaea ohmeri, Aureobasidium spp, positive histopathology only (septate hyphae).
gTwo patients had 2 distinct courses of isavuconazole therapy for the same IFI episode. The interval between courses was 12 and 29 days, respectively.
hFirst-line prophylaxis (n = 3), second-line prophylaxis (n = 2).
iIf administered for at least 7 days: echinocandin drug (n = 8), liposomal amphotericin B (n = 7), terbinafine (n = 1).